Recent 8-K filings for ARMP

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 13, 2026 20:33 UTC earnings item 1.01item 2.02item 2.03item 7.01item 9.01

  Armata posts Q1 net loss of $115.3M ($3.16/diluted share); secures $25M Innoviva loan

• May 07, 2026 23:59 UTC regulatory item 7.01item 9.01

  Armata receives FDA Fast Track for AP-SA02 phage therapy for S. aureus bacteremia

• Apr 27, 2026 23:59 UTC leadership item 5.02item 7.01item 9.01

  Armata appoints Dr. Daniel Gilmer to Board; option award for 51,280 shares

• Apr 02, 2026 23:59 UTC other item 8.01

  Armata sets June 11, 2026 for annual meeting; record date April 17

• Mar 25, 2026 23:59 UTC earnings item 2.02item 9.01

  Armata Pharma Q4 net loss $124.3M on $105.8M non-cash fair value loss; going concern noted

• Mar 19, 2026 23:59 UTC other_material item 7.01item 9.01

  Armata delays Q4/FY2025 earnings; FDA grants QIDP for phage candidate AP-SA02

• Feb 23, 2026 23:59 UTC regulatory item 7.01item 9.01

  FDA grants QIDP designation to Armata's AP-SA02 for S. aureus bacteremia

• Jan 26, 2026 23:59 UTC debt item 1.01item 9.01

  Armata extends credit maturity to June 2027 and warrants to Jan 2031 with Innoviva affiliate

• Jan 13, 2026 23:59 UTC regulatory item 7.01item 9.01

  Armata Pharma receives FDA EOP2 support for AP-SA02 Phase 3 in S. aureus bacteremia

• Dec 01, 2025 23:59 UTC other_material item 1.01item 9.01

  Armata enters ATM offering agreement for up to $100M of common stock

• Nov 12, 2025 23:59 UTC earnings item 2.02item 9.01

  Armata Q3 loss from ops $7.8M; AP-SA02 Phase 2a shows efficacy, cGMP facility commissioned

• Oct 22, 2025 23:59 UTC other_material item 7.01item 9.01

  Armata AP-SA02 phage cocktail hits primary endpoint in Phase 2a S. aureus bacteremia trial

• Sep 11, 2025 23:59 UTC other item 7.01item 9.01

  Armata presents at H.C. Wainwright conference; no new data in exhibit

• Aug 12, 2025 23:59 UTC earnings item 1.01item 2.02item 2.03item 7.01item 9.01

  Armata posts Q2 2025 operating loss; announces positive AP-SA02 trial results and $15M credit from Innoviva

source · ARMP on sec.gov